The Employers’ Guide to GLP-1s
- White Paper
- Obesity care and GLP-1s
- July 31
- 1 min read
Summary
As the demand for GLP-1s continues to surge, it’s no surprise they’re now among the top-cost drugs for employers. In this white paper, learn everything you need to know about GLP-1s to guide your obesity care strategy.
Breakthrough anti-obesity medications called GLP-1s have revolutionized the treatment landscape for obesity. While these medications have proven effective, they can be costly. If just half of those eligible sought GLP-1s for weight loss, prescription costs could increase by more than $840 per member per year across the entire population. Now more than ever before, employers need a proactive GLP-1 strategy to eliminate unnecessary spend, while optimizing health outcomes.
In this white paper, you’ll discover:
- The latest evidence behind GLP-1s
- Why GLP-1s may not be for everyone
- The importance of a multidisciplinary, stepped care approach to sustain long-term health outcomes and control costs
Download the White Paper
By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.
